The ezperimental study of lung carcinoma vaccine modified by human B7-1 and IFN-γ genes
With the advance of immunology, immunogene therapy is becoming a possible therapeutic alternative to advanced cancer. The aim of tumor immunogene therapy is to enhance the immune response to tumors. Evidence suggests that CD80 (B7-1) and Interferon-gamma (IFN-γ) play important roles in antitumor immunity induced by T lymphocyte. To study the antitumor immune effects of lung carcinoma vaccine modified with human B7-1 and IFN-γ genes, we constructed the bicistronic retroviral vector pLXSN, encoding human B7-1 and IFN-g. In vitro, the primary lung carcinoma cells were transduced with the retroviral vector and prepared as a vaccine. Then autologous lymphocytes were irritated with the lung carcinoma cells for competition inhibitory cytotoxic testing. The tumor-specific cytotoxic activity was greatly enhanced by the double gene---modified vaccine. In vivo, the tumorigenicity of the double gene---modified lung cell line A-549/B7-1·IFN-γ was evaluated in a human immune reconstituted SCID mice (hu-PBL-SCID) model. The double-gene modification markedly decreases tumor genecity. Together, the results suggest that combining B7-1 and IFN-γ could be a useful therapeutic approach in lung cancer.
B7-1(CD80) IFN-γ immunotherapy lung carcinoma vaccine retroviral vector
Shi-Ying ZHENG Dong JIANG Jun ZHAO Jin-Feng GE Hong LI
Department of Cardio-Thoracic Surgery,The First Affiliated Hospital of Suzhou University,Suzhou 2150 Department of Geriatrics,The First Affiliated Hospital of Suzhou University,Suzhou,Jiangsu Province,
国际会议
北京
英文
1-7
2009-06-11（万方平台首次上网日期，不代表论文的发表时间）